Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|ER-positive Breast Cancer
Interventions: DRUG: fulvestrant 500 mg|DRUG: Docetaxel|DRUG: Trastuzumab (H, 8mg/kg|DRUG: Pertuzumab (P, 840 mg
Sponsor: Western Regional Medical Center